ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Enhancing diagnostic precision in Alzheimer's disease: Impact of comorbidities on blood biomarkers for clinical integration.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic accuracy of plasma p-tau217 against amyloid PET: A meta-analysis of technical platform variability and ratio versus single marker comparisons.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Pooled it
- Comparative Analysis of Plasma Biomarkers of Alzheimer's Disease and Frontotemporal Dementia: The Dual Role of Soluble Fractalkine as a Biomarker of Frontotemporal Dementia and Its Neuroprotective Effects in Cortical Neurons "In Vitro".Life (Basel, Switzerland) · 2026Article
- Worry and Anxiety in the Era of Early Diagnosis and Disease Modifying Treatment for Alzheimer's Disease.Current psychiatry reports · 2026Review
- Reliable quantification of renal function from frozen blood samples.medRxiv : the preprint server for health sciences · 2026Article
- Peripheral Syndecan-3 and Neurofilament Light Chain as Complementary Blood Biomarkers for Alzheimer's Disease.International journal of molecular sciences · 2026Article
- Blood-based biomarkers for Alzheimer's disease: influence of kidney function.Alzheimer's research & therapy · 2026Article
- Enhancing diagnostic precision in Alzheimer's disease: Impact of comorbidities on blood biomarkers for clinical integration.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionComorbidities may influence Alzheimer's disease (AD) plasma biomarkers. This study aimed to investigate how medical conditions impact AD plasma biomarkers and whether comorbidity-adjusted models enhance their diagnostic performance.
methodsWe analyzed key AD plasma biomarkers in 311 memory clinic patients (mean age 59 years, 57% female) at Karolinska University Hospital, Sweden. Biomarkers were measured using single molecular array (SIMOA) and Lumipulse assay. Multivariate linear regressions and receiver operating characteristic/area under the curves (ROC/AUCs) were calculated using clinical diagnosis and cerebrospinal fluid biomarkers as gold standards.
resultsPlasma biomarkers were associated with comorbidities and metabolites such as estimated glomerular filtration rate, homocysteine, and high-density lipoprotein. Phosphorylated tau (p-tau)/amyloid beta (Aβ)42 and p-tau217 had excellent performances in AD pathology classification (AUCs > 0.938). Adjusting for comorbidity measures significantly improved the diagnostic accuracy of Aβ42/40. DISCUSSION: In conclusion, plasma biomarkers performed robustly despite comorbidity associations, with p-tau217 emerging as the strongest discriminator. These findings support their potential as diagnostic tools in clinical settings. HIGHLIGHTS: Plasma biomarkers for Alzheimer's disease (AD) were assessed in a real-world memory clinic population. Kidney dysfunction and cardiovascular risk factors influenced plasma biomarker levels. Phosphorylated tau (p-tau)217 and p-tau217/amyloid beta (Aβ)42 ratio showed strongest association with AD pathology. Aβ42/40 ratio's accuracy was improved by including comorbidities into the diagnostic algorithms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.